Rachel Nicola MacCoss

This inventor holds 8 USPTO granted patents. Top assignees: Merck Sharp + Dohme Corp., Msd K.k.. Active years: 2012-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rachel Nicola MacCoss. Retrieved from https://idiyas.com/inventor/rachel-nicola-maccoss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8

% Patents Active = 87.5

Average Co-Inventor Count = 12.3

ph-index = 3

Forward Citations = 38(Granted Patents)

Location History:

Brookline, MA (US) (2012 - 2014)
Oxford, GB (2013 - 2015)

Company Filing History:

8 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2012-2015

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8927559 - [object Object] (2015-01-06),

2. 8871796 - Diaryl ether derivatives as notch sparing gamma secretase inhibitors (2014-10-28),

3. 8592383 - [object Object] (2013-11-26),

4. 8575150 - Triazole derivatives for treatment of Alzheimer's disease (2013-11-05),

5. 8455477 - Therapeutic compounds (2013-06-04),

6. 8367706 - Inhibitors of janus kinases (2013-02-05),

7. 8344144 - Inhibitors of Janus kinases (2013-01-01),

8. 8329722 - Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 (2012-12-11),

Title: Rachel Nicola MacCoss: Innovator in Pharmaceutical Chemistry

Introduction

Rachel Nicola MacCoss is a prominent inventor based in Brookline, MA (US), known for her significant contributions to pharmaceutical chemistry. With a total of eight patents to her name, she has made remarkable strides in the development of compounds aimed at treating various disease states.

Latest Patents

Among her latest patents is an application that provides for compounds of a specific formula, along with processes to prepare these compounds and their use in treating diseases associated with the CRTH receptor. Another notable invention encompasses a novel class of diaryl ether derivatives that inhibit the processing of APP by the putative gamma-secretase while sparing the Notch signaling pathway. This innovation is particularly useful in the treatment or prevention of Alzheimer's disease, addressing the gastrointestinal issues often associated with Notch inhibition.

Career Highlights

Rachel has worked with esteemed companies such as Merck Sharp & Dohme Corporation and MSD K.K., where she has applied her expertise in pharmaceutical development. Her work has been instrumental in advancing therapeutic options for patients.

Collaborations

Throughout her career, Rachel has collaborated with talented individuals, including Joon Jung and Phieng Siliphaivanh, contributing to a dynamic research environment.

Conclusion

Rachel Nicola MacCoss stands out as an influential inventor in the field of pharmaceutical chemistry, with her innovative patents paving the way for new treatments. Her dedication to research and collaboration continues to impact the industry positively.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]